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Abstract: Research on liposome formulations has progressed from that on conventional vesicles 
to new generation liposomes, such as cationic liposomes, temperature sensitive liposomes, and 
virosomes, by modulating the formulation techniques and lipid composition. Many research 
papers focus on the correlation of blood circulation time and drug accumulation in target tissues 
with physicochemical properties of liposomal formulations, including particle size, membrane 
lamellarity, surface charge, permeability, encapsulation volume, shelf time, and release rate. 
This review is mainly to compare the therapeutic effect of current clinically approved liposome-
based drugs with free drugs, and to also determine the clinical effect via liposomal variations in 
lipid composition. Furthermore, the major preclinical and clinical data related to the principal 
liposomal formulations are also summarized.
Keywords: PEGlated liposomes, temperature sensitive liposomes, therapeutic efficiency, 
virosomes, cationic liposomes
Introduction
The clinical utility of most conventional chemotherapeutics is limited either by the 
inability to deliver therapeutic drug concentrations to the target tissues or by severe 
and harmful toxic effects on normal organs and tissues. Liposomes are small, spheri-
cal, and enclosed compartments separating an aqueous medium from another by 
phospholipid bilayer. Many hundreds of drugs, including anticancer and antimicrobial 
agents, chelating agents, peptide hormones, enzymes, proteins, vaccines, and genetic 
materials, have been incorporated into the aqueous or lipid phases of liposomes, with 
various sizes, compositions, and other characteristics, to provide selective delivery 
to the target site for in vivo application. Several techniques, such as the Bangham, 
detergent-depletion, ether/ethanol injection, reverse phase evaporation, and emulsion 
methods, have been reported for preparing liposomes with high-entrapment efficiency, 
narrow particle size distribution, and long-term stability.1–7 Recently, some alternative 
methods including dense gas and supercritical fluid techniques have been introduced 
for liposome preparation without using any organic solvent.1,7–9 Due to the differences 
in preparation methods and lipid compositions, liposomes can be classified according 
to their lamellarity (uni- and multilamellar vesicles), size (small [#100 nm], inter-
mediate [100–250 nm], or large [$250 nm]), and surface charge (anionic, cationic, 
or neutral).10–12 In clinical studies, liposomes show improved pharmacokinetics and 
biodistribution of therapeutic agents and thus minimize toxicity by their accumulation 
at the target tissue.13,14
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Liposomes were first discovered by Bangham in 1965 and 
the first liposomal pharmaceutical product, Doxil®, (Ben Venue 
Laboratories, Inc Bedford, OH) received US Food and Drug 
Administration (FDA) approval in 1995 for the treatment of 
chemotherapy refractory acquired immune deficiency syndrome 
(AIDS)-related Kaposi’s sarcoma.13–15 Currently, there are about 
twelve liposome-based drugs approved for clinical use and more 
are in various stages of clinical trials (Tables 1 and 2).13–62 Most 
liposomal drug formulations, such as Doxil and Myocet™ (GP-
Pharm, Barcelona, Spain), are approved for intravenous applica-
tion.63 Other administration routes such as intramuscular delivery 
have been approved for delivery of surface antigens derived 
from the hepatitis A or influenza virus (Epaxal® [Berna Biotech 
Ltd, Berne Switzerland] and Inflexal® V [Berna Biotech España 
SA, Madrid, Spain]).37,38 Oral delivery has also been examined; 
however, this is more troublesome due to the potential for lipo-
some breakdown following exposure to bile salts.64
Storage of liposomes: lyophilization
Liposomes dispersed in aqueous solution generally face 
physical and chemical instabilities after long-term storage.65 
  Hydrolysis and oxidation of phospholipids and liposome 
aggregation are the common cause of liposome   instabilities. 
According to the literature, many methods have been investi-
gated for the stabilization of liposomes, such as lyophilization, 
freezing, and spraying drying. In commercial liposome-based 
drugs (Table 1), AmBisome® (Gilead Sciences, Inc, San 
Dimas, CA), Amphotec® (Ben Venue Laboratories, Inc, 
Bedford, OH), Myocet, Visudyne® (Novartis Pharma AG, 
Basel, Switzerland), and LEP-ETU (liposome-entrapped 
paclitaxel easy-to-use; NeoPharm, Inc, Lake Bluff, IL) are 
all lyophilized products. In general, freeze-drying increases 
the shelf-life of liposomal formulations and preserves them 
in dried form as lyophilized cakes to be reconstituted with 
water for injection prior to administration.66 Furthermore, 
cryoprotectants need to be added to maintain particle size 
distribution of liposomes after the freeze-drying-rehydration 
cycle. Various types and concentrations of sugars have been 
investigated for their ability to protect liposomes against 
fusion and leakage during lyophilization processes.66 In com-
mercial liposome lyophilized products, lactose has been used 
as a cryoprotectant in the formulations of Amphotec, Myocet, 
and Visudyne, and sucrose was added in the formulations of 
AmBisome and LEP-ETU to increase liposome stability dur-
ing lyophilization. Interestingly, these commercial lyophilized 
products showed similar shelf-life in comparison with other 
liposome products (eg, suspension and emulsions) and hence 
lyophilization may not have the expected effect on liposome 
stability. In 1998, Clemons and Stevens compared the potency 
and therapeutic efficacy among the different lipid-based 
formulations of amphotericin B (Amphotec, AmBisome, and 
Abelcet® (Sigma-Tau PharmaSource, Inc, Indianapolis, IN)) 
for the treatment of systemic and meningeal cryptococcal 
  disease.67 Their work indicated that the therapeutic efficacy 
of Amphotec and AmBisome was superior to that of Abelcet, 
by up to ten-fold, in survival and in clearing infection from 
all organs. In these three commercially available lipid-based 
formulations of amphotericin B, Amphotec and AmBisome 
are both lyophilized products and Abelcet is formulated as 
a   suspension. Therefore, lyophilization may not extend the 
shelf-life of products but may increase therapeutic efficacy 
in vivo. Similar results were also reported in our previous 
studies.70 We investigated the stability of the siRNA-loaded 
liposomes in suspension and lyophilized powder form up 
to 1 month postmanufacture.68 Following formulation, the 
siRNA-loaded liposomes were stored at either 4°C or room 
temperature. The particle size and zeta potential of siRNA-
loaded liposomes remained unchanged in both storage 
  conditions. However, siRNA entrapment efficiencies were 
observed to have decreased slightly after 1 month in storage 
for both suspension (90% → 83%) and lyophilized powder 
(94% → 84%) forms. Surprisingly, the gene-silencing 
efficiency of siRNA-loaded liposomes in aqueous solution 
showed 80% reduction following 1 month of storage at either 
4°C or room temperature. This was in contrast to liposomes 
prepared in the lyophilized powder form where 100% of the 
gene-silencing efficiency was retained following storage 
at either 4°C or room temperature for 1 month. Although 
therapeutic efficiency of liposome-based drugs may vary 
depending on the choice of lipids, the preparation technique, 
physico-chemical characteristics of the bioactive materials, 
and overall charge of the liposome, lyophilization is useful 
for the long-term storage of liposome-based drugs.
Clinical studies of liposomal-based 
anticancer drugs: doxorubicin
Liposome delivery systems offer the potential to enhance the 
therapeutic index of anticancer drugs, either by increasing the 
drug concentration in tumor cells or by decreasing the expo-
sure in normal host tissues. Doxorubicin is an anthracycline 
widely used to treat solid and hematological tumors, but its 
major drawback is its related cardiotoxicity. In cardiotoxicity, 
positively charged doxorubicin’s affinity for negatively charged 
cardiolipin, a lipid abundant in heart tissue, is thought to be 
involved in drug localization in the heart tissue.69 Therefore, 
doxorubicin-loaded liposomes were developed to combat 
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Figure 1 Chemical structures of lipids in liposome formulations.
Abbreviations: DOTAP, 1,2-dioleoyl-3-trimethylammonium propane; DPPC, dipalmitoylphosphatidylcholine; DOPA, 1,2-Dioleoyl-sn-Glycero-3-Phosphate; 
MSPC,  monostearoylphosphatidylcholine;  DPPG,  dipalmitoylphosphatidylglycerol;  DSPC,  distearoylphosphatidylcholine;  HSPC,  hydrogenated  soy  PC;  DMPG,  l-α-
dimyristoylphosphatidylglycerol; DMPC, 1-α-dimyristoylphosphatidylcholine; DOPC, 1,2-Dioleoyl-sn-glycero-3-phosphocholine; DOPE, dioleoyl phosphatidylethanolamine; 
DSPG, distearoylphosphatidylglycerol; PEG2000-DSPE , polyethylene glycol 2000-distearoylphosphatidylethanolamine.
aggressive tumors, like breast and ovary metastatic cancers and 
Kaposi’s sarcoma. Myocet and Doxil were the first-approved 
liposome-based drugs for cancer treatment. Both products 
contain doxorubicin but are different, particularly in the pres-
ence of polyethylene glycol (PEG) coating (Figure 1). In phar-
macokinetic studies of doxorubicin-loaded liposomes, free 
doxorubicin had an elimination half-life of 0.2 hours and an 
area under the plasma concentration–time curve (AU) of 4 µg h 
mL–1 in patients as compared with 2.5 hours and 45 µg h mL–1 
for Myocet and with 55 hours and 900 µg h mL–1 for Doxil, 
respectively.25 The particle size of Myocet is about 190 nm and 
Doxil is about 100 nm. Both liposome products have longer 
circulating half-life in blood as compared with the free drug, 
but Doxil has a much longer circulation time in blood than 
  Myocet. Generally, the blood circulation time of liposomes 
(T1/2) increases with decreasing size, negative charge density, 
and fluidity in the bilayer or PEG surface coating. In a Phase III 
head-to-head comparison of free   doxorubicin vs Myocet in 
patients with metastatic breast cancer, similar results were 
presented in first-year survival rate (64% vs 69%) and 
progression-free survival (3.8 vs 4.3 months), but Myo-
cet had low incidence of cardiac events (13% vs 29%), 
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mucositis/stomatitis (8.6% vs 11.9%), and nausea/vomiting   
(12.3% vs 20.3%).70,71 Therefore, Myocet tends to reduce 
drug-related toxicity (eg, cardiotoxicity) rather than to enhance 
antitumor efficacy. Similar to Myocet, Doxil had a better safety 
profile, including reduction of   cardiotoxicity (3.9% vs 18.8%), 
neutropenia (4% vs 10%), vomiting (19% vs 31%), and alope-
cia (20% vs 66%) in a Phase III trial of metastatic breast cancer, 
whereas its progression-free survival times (6.9 vs 7.8 months) 
and overall survival times (21 vs 22 months) demonstrated 
equivalent efficacy to conventional   doxorubicin.72 However, 
palmar-plantar erythrodysesthesia (48% vs 2%), stomatitis 
(22% vs 15%), and mucositis (23% vs 13%) were found to be 
more often associated with Doxil than free doxorubicin.
Lipo-dox® (TTY Biopharm Company Ltd, Taipei Taiwan) 
is the second generation of PEGylated liposomal doxorubi-
cin, composed of distearoylphosphatidylcholine (DSPC) and 
cholesterol with a surface coating of PEG.27 DSPC, which 
has two completely saturated fatty acids (both stearic acids), 
has high phase-transition temperature (Tm), 55°C, and good 
compatibility with cholesterol. Normally, lipid bilayer has two 
thermodynamic phases: gel or liquid-crystal phase. At tem-
perature , Tm, the lipid membrane is in the gel phase, which 
is relatively rigid and tight because the lipid molecules have 
lower energy of random motion and the hydrocarbon chains 
are fully extended and closely packed. Liposomes composed 
of phospholipids like DSPC have higher stability compared 
with others containing unsaturated fatty acid (egg phosphati-
dycholine [PC]) or fatty acids of shorter or not uniform carbon 
chains like hydrogenated soy PC (HSPC). In a Phase I clini-
cal study, Lipo-dox achieved the most prolonged circulation 
half-life (65 hours).73 However, Tseng et al demonstrated that 
there were no differences in survival between free doxorubicin 
only (median survival time of 23 days) and Lipo-dox (medium 
survival time of 23.5 days) in a murine B-cell lymphoma 
model.74 In patients with metastatic breast cancer, the median 
time to disease progression of 163 days represented the result 
of Lipo-dox treatment and the median duration of response 
in responding patients (286 days) are comparable with those 
of Doxil treatment.75 Neutropenia, stomatitis, and skin toxic-
ity were reported in many cases of Lipo-dox administration. 
Moreover, stomatitis became the new dose-limiting toxicity 
of PEGylated liposomal   doxorubicin. For Lipo-dox, stoma-
titis appeared at doses of 30 mg/m2 and reached dose limit at 
50 mg/m2.27 In contrast, Doxil reached dose limit at 80 mg/m2 
and hence Lipo-dox had higher incidence of severe stomatitis 
than Doxil. In comparison with Myocet (the non-PEGylated 
form of liposomal doxorubicin), Doxil and Lipo-dox (both 
PEGylated forms of liposomal doxorubicin) both showed 
significant incidence of stomatitis and this is mainly due to the 
long circulation properties of PEGylated liposomes.27,71,72
The new generation of doxorubicin-loaded liposomes 
are thermosensitive liposomes (TSLs), which release their 
encapsulated drugs in regions where local tissue temperatures 
are elevated.76 Compared with non-TSLs that remain stable 
and do not release drug in the physiologic temperature range, 
TSLs undergo a gel-to-liquid crystalline phase change when 
heated that renders the liposomes more permeable, releasing 
their encapsulated drugs. ThermoDox® (Celsion Corpora-
tion, Lawrenceville, NJ), a proprietary TSL encapsulation of 
doxorubicin, has recently begun Phase III clinical trials for 
the treatment of hepatocellular carcinoma.77 ThermoDox is 
composed of dipalmitoylphosphatidylcholine (DPPC), monos-
tearoylphosphatidylcholine (MSPC), and polyethylene glycol 
2000-distearoylphosphatidylethanolamine (PEG 2000-DSPE) 
in 90:10:4 molar ratio.49,50 In the design of TSLs, it is necessary 
to choose a phospholipid that has a gel-to-liquid crystalline 
phase transition temperature (Tc) in the temperature range 
of clinically attainable local hyperthermia (41°C– 42°C). 
The mechanism behind TSLs is the temperature-induced 
membrane instability at the Tc of the used lipids. DPPC with 
a Tc = 41.5°C is an ideal lipid according to temperature-trig-
gered technology.78,79 For liposomes composed of DPPC alone, 
the rate of release and the amount released are relatively small. 
By incorporating a small amount of lysolipids, such as MSPC 
or monopalmitoylphosphatidylcholine, into DPPC liposomes, 
Tc is shifted down slightly and membrane instability and drug 
release rate is significantly enhanced at Tc. In vitro release 
studies, monopalmitoylphosphatidylcholine-containing TSLs 
released about 45% of encapsulated doxorubicin in bovine 
serum at 42°C in a few seconds (20 seconds), while pure 
DPPC liposomes released only 20% over 1 hour.79 Banno 
et al demonstrated that the presence of MSPC, rather than 
PEG 2000-DSPE, in DPPC liposomes would give rise to the 
rapid drug-release profile in vitro, suggesting that lysolipid 
is the more important component in determining the rate of 
TSL content release.80 Indeed, Banno’s in vivo data showed 
that the presence of 9.6 mol% MSPC in TSL could result 
in more rapid elimination of the encapsulated doxorubicin 
(T1/2 = 1.29 h), compared with the formulation without 
lysolipid (T1/2 = 2.91 h). In 2007, Dromi et al compared the 
accumulation of doxorubicin in mice tumors among free 
doxorubicin, Doxil, and ThermoDox.50 Results showed that 
over time, doxorubicin gradually increased in tumors when 
both Doxil and ThermoDox were used but not with free 
doxorubicin. At 24 hours after administration, doxorubicin 
concentrations in tumors were found to be significantly higher 
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with Doxil than ThermoDox. ThermoDox is currently under 
evaluation in clinical trials and hence the therapeutic efficacy 
of ThermoDox is still unknown.
Clinical studies of liposomal-based 
anticancer drugs: daunorubicin
Daunorubicin is classified as an anthracycline anticancer 
drug in the treatment of leukemia and a wide variety of solid 
tumors, but its major drawbacks are myelosuppression and 
cardiotoxicity.81 Daunorubicin has also been incorporated 
into liposomes for the formulation of liposomal anticancer 
chemotherapy drugs. DaunoXome® (Gilead Sciences, Inc) is a 
commercial liposomal formulation of daunorubicin in which 
the drug is entrapped into small unilamellar vesicles (45 nm) 
composed of DSPC and cholesterol in 2:1 molar ratio. In 
animal studies with tumor models in mice, DaunoXome 
increased tumor uptake of daunorubicin ten-fold when 
measured against free drug (2470.5 vs 245.1 µg ⋅ hr/mL for 
0–48 hours).82   Furthermore, clinical pharmacokinetic stud-
ies have demonstrated that DaunoXome was 36-fold higher 
in AUC (375.3 vs 10.33 µg ⋅ hr/mL) in comparison with 
conventional   daunorubicin.83 In a Phase III trial of DaunoX-
ome versus a conventional combination of doxorubicin, 
bleomycin, and vincristine (ABV) in AIDS-related Kaposi’s 
sarcoma, the efficacy of   DaunoXome was comparable to that 
of vincristine. Response rates (25% vs 28%), time to treat-
ment failure (115 vs 99 days), and overall survival (369 vs 
342 days) were similar on both treatment arms.84 Moreover, 
patients treated with DaunoXome experienced less alopecia 
(8% vs 36%) and neuropathy (13% vs 41%) and their car-
diac function remained stable. Therefore, DaunoXome may 
provide another comparable but safer chemotherapy.
Clinical studies of liposomal-based 
anticancer drugs: paclitaxel
Taxol® (paclitaxel) is a marketed product for the treatment of 
ovarian, breast, non-small cell lung cancer, and AIDS-related 
Kaposi’s sarcoma.40 However, paclitaxel is only sparingly 
soluble in water and, therefore, intravenous administration 
depends on the use of the non-ionic surfactant Cremophor 
EL® (polyethoxylated castor oil) to achieve a clinically rel-
evant concentrated solution. Unfortunately, Cremophor EL 
increases toxicity and leads to hypersensitivity reactions in 
certain patients.85 The LEP-ETU formulation of paclitaxel 
is being developed to potentially reduce toxicities associ-
ated with Taxol by eliminating the drug formulation com-
ponent polyoxyethylated castor oil. LEP-ETU formulations 
composed of 1,2-Dioleoyl-sn-glycero-3-phosphocholine 
(DOPC), cholesterol, and cardiolipin in 90:5:5 molar ratio 
were prepared by the modified thin-film hydration method. 
DOPC, a zwitterionic natural phospholipid, is chosen as 
one of the lipid components in the LEP-ETU formulation 
because of a low Tc (−22°C) and hence DOPC can form 
more flexible liposomes to entrap highly hydrophobic 
molecules. Moreover, cholesterol is included in LEP-ETU 
formulations to increase the liposome stability. Liposomes 
containing cardiolipin reportedly reduced cardiotoxicity 
associated with doxorubicin by altering the pharmacokinetics 
and   tissue distribution of the drug and hence cardiolipin may 
also exert similar results in LEP-ETU.86 Fetterly et al evalu-
ated the maximum tolerated dose, dose-limiting toxicities, 
and pharmacokinetics of liposome-encapsulated paclitaxel 
(LEP-ETU) in comparison with Taxol.87,88 The maximum 
tolerated dose of LEP-ETU was 325 mg/m2 in a Phase I study 
of patients with locally advanced or metastatic carcinoma.88,89 
This dose is higher than that achieved with Taxol, which is 
typically delivered at a dose range of 135 to 200 mg/m2. The 
major toxicity to administration of paclitaxel is neuropathy. In 
the Phase I study, neurotoxicity occurred in 5 of 12 patients 
(42%) treated with LEP-ETU at $325 mg/m2. Although a 
direct comparison with Taxol is not possible, neutropenia 
was seen in 53% of metastatic breast cancer patients treated 
with 250 mg/m2 Taxol as demonstrated by Winer et al.89 
Therefore, the neuropathy caused by LEP-ETU appears to 
be no worse than that reported for Taxol within 3 weeks of 
treatment. Following LEP-ETU administration, the AUC of 
paclitaxel in patients with advanced or metastatic carcinoma 
was improved (8.2 to 6.16 µg ⋅ hr/mL) with increasing dose 
(135 to 375 mg/m2), which is similar to Taxol. Although 
similarities exist between the plasma pharmacokinetics of 
the two formulations, the clinical evidence obtained from the 
Phase I study shows LEP-ETU can be administered safely at 
higher doses than Taxol.88,89
Another  liposome  formation  of  paclitaxel  is 
EndoTAG-1.42–44 The formulation of EndoTAG-1 is prepared 
by 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), 
DOPC, and paclitaxel in 50:47:3 molar ratio. DOTAP is a 
cationic synthetic lipid, which comprises one positive charge 
at the head group. The use of cationic lipids to enhance gene 
delivery has been studied extensively, but their application 
in clinic is relatively unexplored. Recently, there has been 
great interest in cationic liposomes, mainly due to their 
inherent ability to selectively target tumor vasculature. This 
selective affinity of cationic liposomes to tumor vasculature 
provides an opportunity for the development of many anti-
angiogenic and anticancer formulations based on cationic 
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liposomes.42 EndoTAG-1 is the first formulation of cationic 
liposomes carrying paclitaxel in clinical trial. For com-
mercial storage, EndoTAG-1 formulations are lyophilized, 
and they are reconstituted with water for injection directly 
prior use. In preclinical programs, EndoTAG1-1 inhibited 
tumor growth also in Taxol-resistant animal tumor mod-
els such as B16 melanoma and Sk-Mel 28 melanoma. 
EndoTAG-1 demonstrated a strong antivascular effect on 
the preexisting tumor vasculature and affected several tumor 
  microcirculatory parameters. In a Phase II trial of patients 
with pancreatic adenocarcinoma who were not candidates 
for surgery, EndoTAG-1 in combination with gemcitabine 
substantially extended overall survival compared with gem-
citabine alone.90 Median survival in patients who received 
gemcitabine alone was 7.2 months, whereas it was up to 
9.4 months in those who received combination treatment 
of EndoTAG-1 plus gemcitabine. After 6 and 12 months 
of treatment, survival rate was superior for all EndoTAG-1 
doses plus gemcitabine compared with gemcitabine alone. 
The 12-month survival rates in patients given the two higher 
doses of EndoTAG-1 (22 and 44 mg/m2 plus gemcitabine) 
were 36% and 33%, respectively, compared with 17.5% in 
those given gemcitabine alone. Combination treatment with 
EndoTAG-1 plus gemcitabine was well tolerated and led to 
substantially more prolonged survival rates compared with 
standard therapy in this Phase II trial. Further clinical studies 
are warranted to demonstrate a statistically significant sur-
vival benefit associated with EndoTAG-1 plus gemcitabine 
in advanced pancreatic cancer.
Liposome application in vaccine 
formulation: Epaxal and Inflexal V
The incorporation of viral membrane proteins or peptide 
antigens into liposomes has been shown to potentiate cell-
mediated and humoral immune response, and generate solid 
and durable immunity against the pathogen. Virosomes 
are reconstituted virus liposomes, constructed without the 
genetic information of the virus making them unable to rep-
licate or cause infection.91,92 The lipid layers of virosomes, 
composed of dioleoyl phosphatidylethanolamine (DOPE) and 
DOPC, are employed to mimic viral membrane for vaccine 
delivery. Epaxal and Inflexal V are both vaccine products 
using the virosome-based antigen delivery system for com-
mercial use (Table 1). For the production of Inflexal V , the 
influenza viruses, grown in hens’ eggs, are first inactivated 
with beta-propiolactone. The influenza surface antigens, 
hemagglutinin and neuraminidase, are then purified and 
mixed with the phospholipid lecithin to form virosomes. 
Due to the virosomal technology, hepatitis A virus (HAV) 
vaccine Epaxal, and influenza vaccine Inflexal V are highly 
efficacious by mimicking natural viral infection. The use of 
virosomes to deliver hepatitis A or influenza antigens stimu-
lates a strong immune response of immunocompetent cells. 
In contrast to other commercially available HAV vaccines, 
Epaxal is an aluminium-free vaccine based on formalin-
inactivated hepatitis A (strain RG-SB) antigen-incorporated 
virosomes. In a clinical study by Usonis et al, seroprotection 
rates were 100% in all infants and children at 1 and 12 months 
after primary vaccination with Epaxal.35 In contrast, the 
seroprotection rate after vaccination with the aluminium-
containing vaccine Havrix™ (GlaxoSmithKline Biologicals 
Rixensart, Belgium) was 67.7% in infants with pre-existing 
maternal anti-HAV antibodies, and a booster vaccination 
was required for complete seroprotection. Moreover, Epaxal 
was generally well tolerated by infants and children, with no 
serious systemic or local events reported after either primary 
or booster vaccination.
For Inflexal V , most studies have shown inferior efficacy 
or ineffectiveness on clinical parameters for these vaccines 
compared with the nonadjuvanted, split-virus, or subunit 
seasonal vaccines.93 Kanra et al, compared the immunogenic-
ity and safety of Inflexal V in children with a split influenza 
vaccine, Fluarix (GlaxoSmithKline Biologicals, Dresden, 
Germany).94 Both vaccines were well tolerated and could 
induce effective immune responses in children. Interestingly, 
the virosome-adjuvanted influenza vaccine showed greater 
immunogenicity (88.8% seroconversion rates for H3 N2) over 
the split influenza vaccine (77.5% seroconversion rates for 
H3 N2) in unprimed children. In essence, virosomal tech-
niques may not be able to give superior protective immunity 
in clinic but play an important role in preventing morbidity 
and lethality associated with vaccine.
Liposomal formulations  
in ophthalmology: Visudyne®
Verteporfin is a hydrophobic chlorin-like photosensitizer, 
which has been shown to be highly effective for photo-
dynamic therapy in vivo. However, verteporfin also has a 
tendency to undergo self-aggregation in aqueous media, 
which can severely limit drug bioavailability to biological 
systems. It is important to introduce verteporfin into the 
bloodstream in its monomeric form and hence verteporfin 
was encapsulated in liposomes (Visudyne) for intravenous 
drug delivery.29–31 The lipid layers of Visudyne are composed 
of unsaturated egg phosphatidylglycerol and dimyristoyl 
phosphatidyl choline in 3:5 molar ratio. Visudyne was the 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
56
Chang and YehInternational Journal of Nanomedicine 2012:7
only drug approved by the FDA for the photodynamic treat-
ment of age-related macular degeneration. Visudyne treat-
ment prevents the growth of the destructive blood vessels 
without hurting the surrounding tissues. Phase I and II clini-
cal trials were conducted for 609 patients with age-related 
macular degeneration.95,96 After 12 months of treatment, the 
group treated with Visudyne (6 mg/m2 body surface area) 
had statistically better visual acuity, contrast sensitivity, and 
fluorescein angiographic outcomes than those who had pla-
cebo treatment (5% dextrose in water). At the examination 
12-months posttreatment, 246 (61%) of 402 eyes assigned to 
verteporfin compared with 96 (46%) of 207 eyes assigned to 
placebo had lost fewer than 15 letters of visual acuity from 
baseline. In subgroup analyses, the visual acuity benefit of 
verteporfin therapy was clearly demonstrated (67% vs 39%) 
when the area of choroidal neovascularization, caused by 
age-related macular degeneration, occupied 50% or more 
of the area of the entire lesion. However, Chowdhary et al 
reported that Visudyne was readily destabilized in the pres-
ence of relatively low concentrations of plasma.29 Therefore, 
the aim of future investigation of liposomal formulations in 
ophthalmology is to develop stable liposome structures for 
extending the plasma circulation time following intravenous 
injection.
Future approaches
Since the first liposomal pharmaceutical product, Doxil, 
received FDA approval in 1995, liposomes have been widely 
applied as drug carriers in clinic. Until now, several important 
types of liposomes, such as PEGylated liposomes (Doxil and 
Lipo-dox), temperature sensitive liposomes (ThermoDox), 
cationic liposomes (EndoTAG1-1), and virosomes (Expal 
and Inflexal V) have been investigated for clinic use. In 
contrast with liposomal-based drugs on the market (Table 1), 
liposome-based drugs in clinical trials (Table 2) focused 
more on the types of delivered drugs (eg, Cisplatin, BLP25 
lipopeptide, Grb2 antisense oligodeoxynucleotide, Bacterio-
phage T4 endonuclease 5, etc) and therapeutic applications 
(from topical delivery systems to portable aerosol delivery 
systems). New liposomal formulations, such as PEGylated 
liposomes, may extend blood circulation time, vary drug 
distribution in the body, and hence reduce the possible side 
effects related to the drugs (eg, cardiotoxicity). However, 
PEGylated liposomes (Doxil and Lipo-dox) displayed signifi-
cant incidence of stomatitis in clinical trials, which may be 
related to PEGylation. Moreover, some of the new generation 
liposomes showed only comparable or even poor therapeutic 
efficiency compared with free drug or conventional vesicles 
in clinical trials. In comparison with Doxil, ThermoDox 
displayed significantly weaker doxorubicin accumulation in 
mice tumors at 24 hours after administration.50 EndoTAG-1 
plus gemcitabine and EndoTAG-1 plus paclitaxel achieved 
excellent therapeutic effect in two Phase II clinical trials in 
pancreatic cancer and triple receptor-negative breast cancer, 
but EndoTAG-1 therapy alone in triple receptor-negative 
breast cancer resulted in poor survival rate (34%) and median 
progression-free survival time (3.4 months) in comparison 
with paclitaxel (48% and 3.7 months).97 SPI-077, the first 
liposomal formulation of cisplatin, had limited clinical effi-
cacy in a Phase II clinical trial of advanced non-small cell 
lung cancer, even though SPI-077 demonstrated enhanced 
cisplatin tumor accumulation in preclinical models.98   Similar 
to SPI-077, a Phase II study of liposomal annamycin in the 
treatment of doxorubicin-resistant breast cancer had no 
detectable antitumor activity.99 Although new liposomal-
based drugs have been well studied in preclinical animal mod-
els, these liposomal pharmaceutical products may be unable 
to provide promising therapeutic effects in clinical trials. For 
future development of liposomal-based drugs, the compari-
son of drug circulation time in blood, drug accumulation in 
tissues, and possible toxicity between conventional vesicles 
and new generations of liposomes should be investigated in 
preclinical animal models. Furthermore, there should also be 
focus on the clinical therapeutic effects and toxic side effects 
of liposomal lipid composition.
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